NEO100 and High-Grade Meningioma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnozą mięsak oponowy stopnia II lub III, który pozostał po operacji, progresuje lub nawrócił mimo operacji i radioterapii
- •Zmeasurowana zmiana widoczna w MRI (co najmniej 10 mm w obu wymiarach)
- •Stable lub zmniejszająca się dawka sterydów przez co najmniej 5 dni przed rozpoczęciem badania
- •Wcześniejsza operacja i radioterapia (bez ograniczeń liczby wcześniejszych zabiegów)
- •Możliwość przyjmowania leku cztery razy dziennie przez 28-dniowe cykle
✗ Disqualifies
- •Chemioterapia lub inne badawcze leki w ciągu 14 dni przed startem badania
- •Inne leczenie nowotworów (chemioterapia, radioterapia) w tym samym czasie co badanie
- •Radioterapia lub chirurgia radionuklidowa mniej niż 12 tygodni przed startem badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
University of Southern California
Los Angeles, United States
Sutter Health Research Institute
San Francisco, United States
Saint John Cancer Institute
Santa Monica, United States
Tufts Medical Center
Boston, United States
Baylor Scott and White
Dallas, United States
Trial contact
Chris Beardmore
Chloe Richmond
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.